chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Woke up with right face drooping on 4/24/21. Called family doctor. Was told to go to ER. At the ER, I was diagnosed with Bell?s Palsy.
BAD HEADACHE.; This spontaneous report received from a patient concerned a male of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 30-MAR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 2021, the subject experienced bad headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of bad headache was not reported. This report was non-serious.
Approx 36 hours following injection heavy fatigue sets in.  By 48 hours not leaving bed except for bathroom use.  Heavy fatigue continues for next 72 hours during which eating/drinking possibly 10% of normal.  Likely becomes dehydrated.  Recovery takes a further 5-6 days.  No other pains or symptoms.  No further symptoms once energy levels return to normal.  [[No idea what the difference is between "intramuscular" and anything else.  Why would you even be asking this question of people who are NOT medical professionals?]]
Hyperemic, pruritic, blanching rash on the arms, legs, face and torso; Hyperemic, pruritic, blanching rash on the arms, legs, face and torso; This is a spontaneous report from a contactable physician. A 19-year-old non-pregnant female received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number was not reported), via an unspecified route of administration on 20May2021 (age at the time of vaccination was 19 years) as dose 2, single for covid-19 immunisation. Other medical history was reported as none and known allergies were reported as no. List of any other medications the patient received within 2 weeks of vaccination and concomitant medications were reported as no. It was reported that the patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number was not reported), via an unspecified route of administration on an unspecified date as dose 1, single for covid-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. On an unspecified date in May2021 (in 24 hrs after the second Pfizer vaccine against Covid-19), the patient experienced hyperemic, pruritic, blanching rash on the arms, legs, face and torso. Serious/ Seriousness criteria-Results in death/ Seriousness criteria-Life threatening/ Seriousness criteria-Caused/prolonged hospitalization/ Seriousness criteria-Disabling/Incapacitating/ Seriousness criteria-Congenital anomaly/birth defect were reported as no. Reportedly, the adverse event result in Doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of hyperemic, pruritic, blanching rash on the arms, legs, face and torso which included Zyrtec 10 mg PO once a day. Since the vaccination, the patient has not been tested for COVID-19. The outcome of the events was unknown.  No follow-up attempts are possible. No further information is expected.
Narrative:  Patient was not previously COVID-19 positive and did not have any predisposing factors(PMH, allergies, etc.) for experiencing an adverse drug event. The ADR did not occur at the time of the administration of the vaccine nor was there an ADR that occurred between the observation period and the date of death. Patient had metastatic esophageal adenocarcinoma since diagnosis on 1/17/20. Patient developed sepsis and was admitted on 2/20/21, He eventually required hospice for his cancer disease progression and decreased on 3/22/21.
Client stated that his arm, that had the injection in, has been extremely sore off and on for a month. Client stated that he could not lay on the arm for about 3 weeks.
Several days of itching, scattered red lesions on chest, neck and face.  Diagnosis: Chickenpox may return to school after crusting begins.
Approximately 26 hours after receiving vaccine, right shoulder started to itch.  One tiny hive was noted directly on injection site.  Right shoulder continued to itch and within 5 minutes, multiple hives surrounding injection site were noted, along with redness and soreness around injection site. Right shoulder was also swollen compared to left shoulder. Tylenol 650mg PO and Benadryl 50mg PO were taken, and ice pack was applied to injection site. Within approx 10 minutes itching stopped. Hives resolved approx 1 hour after medication was taken.
After his 6 month shots, he got a fever and screamed a high pitched scream all night and when on vacation a few days later he was diagnosed with a double ear infection.
Employee reports all side affected listed on sheet as well as diarrhea, nausea, and electric shock sensation at injection site. This lasted 3 days, first day was extremely painful.
mom brought pt to clinic 18JUN96 w/lt thigh area sl swollen, very red, 6cm diameter & very warm to touch;t100 advised mom to apply WMP for 1hr p/vax;pt to MD;MD felt rxn was d/t vax;leg area very blotchy in appearance not red;
Headache; generalized body aches; pain in left arm injection site; severe fatigue; chills; mild fever; dizziness; This is a spontaneous report from a contactable consumer (patient). A 30-years-old male patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Formulation: Solution for injection, Lot number: EL3247, Expiration Date: unknown), via an unspecified route of administration in left arm on 17Feb2021 at 03:15 as a single dose for covid-19 immunization. Medical history included ongoing OCD and depression. Concomitant medications included escitalopram (ESCITALOPRAM) 10 mg once daily, Multivitamin. The patient known allergies: Erythromycin and Azithromycin. Historical vaccines included first dose BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EL3247) via Left arm for covid-19 immunization on 27Jan2021. The patient experienced headache, generalized body aches, pain in left arm injection site, severe fatigue, chills, mild fever, dizziness on 18Feb2021 at 05:00 AM. Patient has been tested for COVID-19 with test type: nasal swab on 05Jan2020 with result negative. No other vaccine in four weeks. Patient covid tested post vaccination yes. No covid prior vaccination. No treatment received for the event. The outcome of the events was not recovered.  No follow up attempts are needed. No further information is expected.
Given third MMR (No documentation of second and needed for school) mother states 5 days later had 4 hour of poor response, headache, stomach ache and legs hurt. Mother states pt has had 2 periods of time at 5 days, one yesterday day 10 after immunization when she had fatigue and aches. Mother concerned about encephalitis.
admitted inpatient into a substance treatment facility; at least 13 weeks between the first and second doses; This spontaneous case was reported by a consumer and describes the occurrence of HOSPITALISATION (admitted inpatient into a substance treatment facility) in a 25-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 01-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Aug-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced HOSPITALISATION (admitted inpatient into a substance treatment facility) (seriousness criterion hospitalization) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (at least 13 weeks between the first and second doses). The patient was hospitalized until 09-Jul-2021 due to HOSPITALISATION. On 09-Jul-2021, HOSPITALISATION (admitted inpatient into a substance treatment facility) outcome was unknown. At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (at least 13 weeks between the first and second doses) had resolved.            No concomitant medication were reported. No treatment history were reported.  Patient denies any side effects or any changes after vaccination. Patient stated that there was no way of receiving the second dose vaccination as patient was admitted inpatient into a substance treatment facility until 09JUL2021. Patient is currently still in treatment living in a sober house.  Company comment- This report refers to a case of Inappropriate schedule of product administration for mRNA-1273, lot # unknown with associated AE (Hospitalisation). Very limited information regarding this event has been provided at this time.  Further information has been requested.; Sender's Comments: This report refers to a case of Inappropriate schedule of product administration for mRNA-1273, lot # unknown with associated AE (Hospitalisation). Very limited information regarding this event has been provided at this time.  Further information has been requested.
Pt. received Td on 03/02/04 and Hep A. parent calls in to report large erythematous and indurated area in left arm (where Td was administered) on 03/04/04 states it is warm to the touch and spreading into the pts back. Referred to local urgent care.
Swelling, severe pain, decreased range of motion, fever, nausea lasting approximately 50+ hours with swelling, moderate pain and swelling with decreased range of motion lasting through the time of this report. Treatment: tylenol and antiemetics.
Moderna 2/13/21, 3/13/21. Positive on 10/3/22
PT DEVELOPED SYNCOPE AFTER GETTING HER FLU SHOT.  PT WAS PLACED ON THE FLOOR AND FEET WERE ELEVATED.  EMS CALLED. PT GOT BETTER AND REFUSED EMS.  PT LEFT ON HER OWN WITH HER HUSBAND.
Right deltoid area with a rash, papules, erythema on area of vaccine administration, with pruritus, 3 days after vaccine administered. Physical exam compatible with delayed type hypersensitivity.
Patient is fully vaccinated and boosted on 10/14/2021.  COVID + 1/13/2022 at hospitalization. 75y.o. male with a PMHx of hypertension, hyperlipidemia, diabetes, history of CVA, or concerns disease, CHF, A. fib and migraines who presents to the ER with complaints of shortness of breath.Patient wears 3 L cannula at home. Has been having increased shortness of breath over the past 2 days. He was satting 83% upon arrival to the ER and was placed on 5 L with improvement. CXR: stable.  Completed baricitinib/remdesivir. Toprol 75mg BID ; Eliquis , Digoxin,metoprolol, cardizem. Discharged home.
2nd dose was administered 13 days early. 1st dose on 01/30/2023 2nd dose :07/17/2023; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a 18-month-old female patient who received HAV (Havrix) (batch number 9r5lc, expiry date 02-NOV-2024) for prophylaxis.   Previously administered products included Havrix (received 1st dose on 30th January 2023).   On 17-JUL-2023, the patient received the 2nd dose of Havrix. On 17-JUL-2023, an unknown time after receiving Havrix, the patient experienced drug dose administration interval too short (Verbatim: 2nd dose was administered 13 days early. 1st dose on 01/30/2023 2nd dose :07/17/2023). The outcome of the drug dose administration interval too short was unknown.   Additional Information: GSK receipt date: 27-Jul-2023 The reporter consented to follow-up. The patient received 2nd dose of Havrix earlier than the recommended interval, which led to shortening of vaccine schedule.
Lesion on chin and multiple lesions to suprapubic area. At onset red bumps and have progessed to crusted lesions. At present self innoculator vs opportunistic infections. To be evaluated by primary care manager.
Starting the evening of 05/21, I was getting a stuffy nose and I felt congestion moving down to my chest. I got concerned and I took an at-home COVID-19 test which was positive. I called the doctor and did a telehealth visit where he prescribed Paxlovid. After the 1st dose, my symptoms started to get better. The symptoms only lasted for a few days while on Paxlovid. The fatigue took a little longer to get over but eventually resolved.
Symptoms began around 8:30PM on 05/27/21. started feeling sick, getting chills and fever, back and joint pain. That went throughout the night and was the same all day Friday. Saturday at 4:00 am woke up vomiting and experiences chest pain. By 9 AM the chest pain was so extreme that I had my wife take me to the ER.  Where they said I was having a heart attack. I have been at Hospital in the ICU  since then.
None before   After vaccines later that day had fever high to 102 F for next three days, cough, congestion, and vomiting and 1 episode of diarrhea, ongoing stomach ache.
I had them, and it wasn't that bad; found the shot horrendous; I didn't go back for the second part of vaccination; This case was reported by a consumer via interactive digital media and described the occurrence of shingles in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingles vaccine and the 2nd dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine and not applicable after receiving Shingles vaccine, the patient experienced shingles, feeling bad and incomplete course of vaccination. On an unknown date, the outcome of the shingles, feeling bad and incomplete course of vaccination were unknown.   It was unknown if the reporter considered the shingles and feeling bad to be related to Shingles vaccine.     Additional Information: GSK Receipt Date: 08-Jun-2022 Reporter's Comments: This case was reported by a patient via interactive digital media. The patient stated that he/she found the shingles shot horrendous and worse than shingles. The patient had shingles and stated that it was n0t that bad. The shingles shot was way worse than shingles. The patient did not go back for the second part of vaccination. Additional Supportive Information: Till the time of reporting, the patient did not receive the 2nd shot of Shingles vaccine, which led to incomplete course of vaccination. The follow-up would not be possible as no contact details were available.
10 days after the 3rd Moderna vaccine I woke up with blotchy round and long hives that looked like an allergic reaction. The hives began behind my ear and eventually covered 80% of my body. Most hives are swollen in the shape of a scratch mark and elevated on my skin. Hives remain for 30 minutes before going away but will spread on the body with further irritation. The reaction persisted after steroids were prescribed by an urgent care clinic. Weeks later, the hives were diagnosed by a dermatologist as Spontaneous urticaria (or dermatographia). 8 months later, the spontaneous urticaria has remained, mostly can be triggered by coffee, alcohol, and stress.
Narrative: 77 year old male admitted on July 27 2022 with headache, cough, dyspnea, and mild hypoxia (O2 saturations in low 90s). He had received Moderna vaccine x 4 on January 24 2021, February 22 2021, October 6 2021, May 4 2022. He was treated with remdesivir 200 mg x 1 then 100 mg IV daily x 4 days and dexamethasone 6 mg x 5 days. He had clinical improvement and was discharged hom on 7/31/2022
Information has been received from a registered nurse concerning a 6 year old male who was vaccinated with PRODQUAD in January 2004, and dose of VARIVAX in March 2008. Recently in 2009 the patient was diagnosed with shingles. The patient was not recovered at time of reporting. The patient had an office visit for medical attention. Follow up information was received from the registered nurse concerning the now 6 year old male patient with amoxicillin allergy and CEFTIN who on 14-MAR-2008 (previously reported in January 2004) was vaccinated with a 0.5 ml dose of PRODQUAD (lot #656310/1394F) into the left deltoid at 5 year of age. On 29-JAN-2004 (previous reported in March 2008) the patient was vaccinated with a 0.5 ml dose of VARIVAX (lot #645047/0206N) into the right thigh at 12 month of age. The patient had no medical history or history of chickenpox. He had recent exposure to chickenpox on 18-MAY-2009. His brother was diagnosed with chickenpox on 18-MAY-2009. On 18-MAY-2009 the patient developed shingles. Papules and early vesicle were in a dermatomal distribution along the right flank to mid abdomen on right side. The maximum temperature was 99.1 (ear). Other systemic symptoms included loose bowel movement 1-2 times and decreased appetite. On an unspecified date, the patient recovered. No specimens were obtained for further testing. Follow up information was received from the registered nurse concerning the now 6 year old male student who was intramuscularly vaccinated with the third dose of COMVAX (lot #646075/0368N) into the left thigh on 29-JAN-2004 at 12 month of age. On 14-MAR-2008, the patient was vaccinated with the third dose of DAPTACEL (lot #C2605AA) IM into the right deltoid and the fourth dose of poliovirus vaccine inactivated (unspecified) (lot #20547-A) IM into the right deltoid at 5 year of age. There was no illness at time of vaccination. Subsequently, on 17-MAY-2009 the patient developed abdominal pain and hyperemesis. He was seen at an after hours clinic and was sent to the emergency department (ED). The next afternoon, the patient was seen in the physician's office and was diagnosed with shingles. Follow up information was received from the registered nurse concerning this 6 year old male patient who on 29-JAN-2004 was vaccinated with the third dose of COMVAX (MSD, lot #646075/0368N) IM into the left thigh. On 14-MAR-2009, the patient was vaccinated with the third dose of DAPTACEL (lot #C2605AA) IM into the right deltoid and the fourth dose of poliovirus vaccine inactivated (unspecified) (lot #20547-A) IM into the right deltoid. There was no illness at the time of vaccination. The patient's weight was 43.4 pounds (previously reported as 48 pounds) and height was 47 inches (previously reported as 44 inches). On 17-MAY-2009 (previously reported as 18-MAY-2009), the patient was seen in the office and diagnosed with shingles. On 21-MAY-2009, the patient was doing better when he was seen for recheck. On 25-JUN-2009, the patient recovered, it was noted that the patient was well when he was seen in the office for a white blood cell count. Additional information is not expected.
Patient received first dose COVID vaccine (Pfizer, lot#EW0185) in the left arm on 05/22/21 at 11am from vaccinator, RN. During the client's  second dose appointment on 06/12/2021, client reported to vaccinator RN that he experienced intermittent chest pain with mild SOB approximately 2.5 weeks after receiving the first dose and persisting for 5 days. RN reported information to, Lead RN. RN completed a medical consult. Client reported pain level 3/10, denied radiating pain, denied lightheadedness, dizziness, difficulty swallowing, slurred speech, and numbness or tingling to the extremities. RN received clearance by MD to vaccinate for second dose Pfizer on 06/12/2021.
patient has not received their 2nd dose of the primary series so far; No adverse event; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT ADMINISTRATION INTERRUPTED (patient has not received their 2nd dose of the primary series so far) and NO ADVERSE EVENT (No adverse event) in a 67-year-old female patient who received mRNA-1273 (Spikevax) (batch no. 057A22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 09-Jan-2023, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT ADMINISTRATION INTERRUPTED (patient has not received their 2nd dose of the primary series so far) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT ADMINISTRATION INTERRUPTED (patient has not received their 2nd dose of the primary series so far) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for PRODUCT ADMINISTRATION INTERRUPTED (patient has not received their 2nd dose of the primary series so far).    No concomitant medication details was reported. No treatment medication details was reported.   Reporter did not allow further contact
Flu like symptoms (aches, fever, sniffles).  Difficult breathing (occasionally must use albuterol).  Shot given on Wednesday and still experiencing flu/cold symptoms on Sunday 08June2008.
Five days after the  vaccination, at least three lymph nodes in the same shoulder as the shot was administered (L) swelled up painfully, making moving that arm unpleasant. The tenderness lasted about five days, and the swelling receded a bit, but at least one node is still slightly enlarged and painful to the touch at this time (about 2.5 weeks later).  I did not seek medical care since swollen lymph nodes were listed as a possible side effect of the vaccine, but figured I should probably report it.
12mins post vaccination pt c/o disorientation, stomach upset, dizziness, blurry vision.  Provider assessed and monitored pt.  Juice and crackers given.  Vitals @4:40pm BP 97/50, HR 63, 98% SpO2 on RA -- > @4:49pm 91/53, HR 64, 98% -- > 5:03pm 97/50, 60 -- > 5:10pm 95/60, 63.  Pt reported feeling improvement in sxs.  @5:10pm pt verbalized resolution of sxs and no new/abnormal sxs.  Provider gave OK to release pt.  Pt left w/ mother w/ steady gait, A&Ox4.  ED precautions provided.
Upper arm-Redness, swelling arm turned purple then darkened. Remained for 7 days. Discoloration lasted 1 month. October 26-Severe joint pain lasted 2 weeks October 27-Chills lasted 5 days  October 27- body temperatures 96-97 lasted 5 days October 26 weakness, fatigue-1 week November 1 sinus infection , laringitis 3 weeks
I did not put the tinnitus with it right away as I had more obvious issues going on of major fatigue, swelling of upper arm, lymph node pain under arm and at collar bone, itching that jumped around to various sites on my body for a a day or so. Rash under injection site.  But at some point I realized I was having a high pitched hissing sound in both ears, I would describe it as an almost metallic sound. It was quite noticeable in Nov, Dec, Jan. and has eithe sllightly lessened or I'm growing more used to it.   I did not seek a Dr. just for the tinnitus. I had an appt. scheduled with my Dr. in January and brought it up with him at that time. He said it's possible the it could be related to the booster and gave me to an ENT I could follow up with.    It's hard from me to definitively say it started right after the Booster, as the other side effects had my attention (including at the time of injection- mouth tingling, immediate sinus drainage, some blood pressure fluctuations at the vax site).  I don't work in an industry that would harm my hearing nor have I in the past. So the timing is pretty suspect for tinnitus to emerge.
DTAP reaction of 3cm X 4cm redness at right deltoid area. Tenderness, worse to touch. Treatment was Benadryl q 6 hours and Claritin.